Home  > Clinical Sections & Programs  > Hematology/Oncology  > Research

Hematology/Oncology

Research

The Pediatric Hematology/Oncology faculty and research staff have active programs in clinical, clinical epidemiologic and laboratory research.

All members of the faculty participate in clinical research. Dr. Jack van Hoff currently leads Yale's participation in the Children's Oncology Group, an international pediatric oncology group that engages in cooperative group clinical trials. Dr. van Hoff researches the epidemiology of childhood cancer, as do other faculty in the Section. Dr. Howard Pearson is co-coordinator of the Connecticut State Board of Health Newborn Hemoglobinopathy Screening Program. He also participates in the New England Sickle Cell Consortium. Dr. Farzana Pashankar directs our Sickle Cell Disease Program and conducts clinical trials in childhood cancer and sickle cell anemia. Drs. Pashankar and Pearson participate in the New England Sickle Cell Consortium.

Dr. Nina Kadan-Lottick is responsible for the creation of Yale's new Clinic for Survivors of Childhood Cancer. She is leading our participation in the ALL task force, the ALL Outcomes Committee, and the Late Effects Committee within the Children's Oncology Group, as well as the Childhood Cancer Survivor Clinic initiative of the National Cancer Institute. Dr. Kadan-Lottick also conducts cancer epidemiology studies related to issues of cancer etiology and survivorship. Her current studies include (1) neurocognitive function among individuals treated for standard risk acute lymphoblastic leukemia, (2) quality of life among children enrolled on cooperative oncology therapeutic trials, and (3) bone mineral density, growth, quality of life, education, and risk of subsequent malignancies among children treated for childhood cancer.

Dr. Diana Beardsley leads our involvement in national and regional trials treating coagulopathies. She has also organized a video grand rounds service for the New England Region Hemophilia Center.

Drs. Diana Beardsley and Peter Beardsley maintain active, externally funded laboratory research. Dr. Diana Beardsley has a longstanding program studying the antibody response in ITP. She has developed a mouse model of human ITP which is providing important information on the mechanism of the disease and its response to therapy. Dr. Peter Beardsley's laboratory efforts include the development of novel neoplasic agents and work on the biology of Pediatric Bone Tumors.